BOSTON, Mass. — Sōlaria Biō, a biotechnology company focused on natural solutions for healthy aging, has released new mechanistic research detailing how the gut–bone axis can be leveraged to slow bone loss, providing critical insight into the biological function of its bone-health product, Bōndia™.
The research clarifies how changes in gut barrier integrity and inflammation directly influence bone resorption and density. According to the company, the findings were instrumental in shaping earlier clinical research published this year in Osteoporosis International, which showed that Bōndia™ improves gut barrier function, reduces inflammation, and suppresses bone resorption.
More than half of women over the age of 50 are affected by osteopenia or osteoporosis, conditions commonly associated with declining estrogen levels, chronic inflammation, and changes in the gut microbiome. Sōlaria Biō said Bōndia™ addresses these drivers as a first-in-class, high-potency synbiotic medical food shown in clinical research to improve bone density by 85 percent.
“We are working to shift the bone health conversation toward early intervention, rather than waiting for osteoporosis to develop,” said Catherine Balsam-Schwaber, CEO of Sōlaria Biō. “These findings provide strong, peer-reviewed evidence for how gut-targeted intervention can create a preventative foundation before bone loss reaches critical levels.”
The mechanistic study, published in the December 2025 issue of the Journal for Functional Foods, demonstrated that Bōndia™ strengthens epithelial gut barrier integrity, limiting the movement of inflammatory molecules into the bloodstream. The research also showed reductions in inflammatory immune signaling in models associated with aging and elevated body fat, along with decreased osteoclast activity and inhibition of osteoclast-mediated bone resorption, as measured by lower TRAP and CTX-1 markers.
Sōlaria Biō said the findings represent a major advance in understanding how reducing gut-driven inflammation can produce measurable improvements in bone density and help protect against age-related bone loss, underscoring the company’s emphasis on science-driven and transparent research.
Building on this work, Sōlaria Biō is collaborating with investigators at the Harvard Medical School-affiliated Hebrew SeniorLife Hinda and Arthur Marcus Institute for Aging Research on a large, 18-month clinical trial evaluating Bōndia (SBD111) in 220 women aged 60 and older. Known as the Study To Attenuate Resorption of Skeleton (STARS), the trial is funded by the National Institute on Aging, with additional collaboration from Beth Israel Deaconess Medical Center, Maine Medical Center, and Tufts University.
